

## Special Issue

# Innovative Strategies in Overcoming Antimicrobial Resistance: From Phage Therapy to Combination

### Message from the Guest Editor

Bacteriophages (phages) are viruses that infect, replicate within, and kill bacteria, offering immense potential as a powerful tool in combating antibiotic resistance. There is renewed interest in phage therapy as many bacterial infections are becoming resistant to antibiotics, leaving us with fewer effective treatment options. The killing mechanism of phages differs from that of antibiotics and holds great promise not only in treating infections but also in preventing their spread and minimizing the emergence of antibiotic resistance. In the following Special Issue "Innovative Strategies in Overcoming Antimicrobial Resistance: From Phage Therapy to Combination", we invite your original cutting-edge research (research articles and reviews) that have the potential to contribute to our understanding of phage therapy. The topics covered in this Special Issue include, but are not limited to, the following:

- Novel phage discovery
- Basic phage therapy
- Phage engineering
- Phage +/- antibiotic therapy
- Phage pharmacokinetics

### Guest Editor

Dr. Rajnikant Sharma

Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences,  
University of Southern California, Los Angeles, CA, USA

### Deadline for manuscript submissions

31 December 2025



## Current Issues in Molecular Biology

an Open Access Journal  
by MDPI

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/246505](https://mdpi.com/si/246505)

*Current Issues in Molecular Biology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cimb@mdpi.com](mailto:cimb@mdpi.com)

[mdpi.com/journal/cimb](https://mdpi.com/journal/cimb)





# Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,  
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,  
New Zealand

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC,  
PubMed, Embase, CAPus / SciFinder, FSTA, AGRIS, and  
other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 17.8 days after  
submission; acceptance to publication is undertaken in 2.7  
days (median values for papers published in this journal in  
the first half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and  
reviewer names are published annually in the journal.